Molecular Biology Program

The Dirk Remus Lab

Research

Dirk Remus
Dirk Remus, PhD

Our lab studies the mechanism of eukaryotic chromosome replication. Chromosomes are the carriers of the genetic and epigenetic information and faithful chromosome replication is of fundamental importance for genome maintenance during normal cell proliferation. We employ fully reconstituted yeast and human DNA replication systems to investigate the structure and biochemical mechanism of the eukaryotic replication machinery. A particular focus of the lab is to elucidate the molecular consequences of replication stress, which encompasses conditions that impede the normal progression of replication forks, and which is a major driver of cancer-associated genome instability. Through this approach, we aim to understand how faithful and efficient chromosomal DNA replication is achieved under normal conditions and, conversely, how the replication machinery is affected by and overcomes the diverse array of physical obstacles encountered on the chromosomal template. Ultimately, our work aims to uncover novel cancer therapeutic targets to control the dysregulated proliferation of cancer cells.

View Lab Overview

The Dirk Remus Lab

Publications Highlights

People

Dirk Remus

Dirk Remus, PhD

  • Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.
  • PhD, University of California, Berkeley
remusd@mskcc.org
Email Address
212-639-5263
Office Phone

Members

Administrative Assistant
Sujan Devbhandari
Postdoctoral Fellow
Postdoctoral Associate
Sahil Batra
Research Scholar
Research Scholar
Lucia Wang
GSK Graduate Student
Wen-Hao Wang
Research Technician
Research Technician
Research Fellow
Gerard P. Lynch
Research Fellow
Ademola Adegbemigun
Research Technician
Juan Castaneda
Graduate Student
Research Technician
Syafiq Abd Wahab
Graduate Student

Achievements

  • Louis V. Gerstner, Jr. Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)
  • Long-Term Fellow, EMBO (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Dirk Remus discloses the following relationships and financial interests:

  • AbCellera Biologics Inc.
    Equity
  • Advanced Micro Devices, Inc
    Equity
  • Alphabet Inc
    Equity
  • Arm Holdings plc
    Equity
  • Beam Therapeutics
    Equity
  • CRISPR Therapeutics AG
    Equity
  • Ginkgo Bioworks, Inc.
    Equity
  • INmune Bio, Inc.
    Equity
  • Intel Corporation
    Equity
  • Intellia
    Equity
  • Merck & Co Inc.
    Equity
  • Microsoft Corporation
    Equity
  • Moderna, Inc.
    Equity
  • Novo Nordisk
    Equity
  • NVIDIA Corporation
    Equity
  • Pfizer, Inc.
    Equity
  • Prime Medicine, Inc.
    Equity
  • Recursion Pharmaceuticals
    Equity
  • Repare Therapeutics
    Equity
  • uniQure N.V.
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures